The development of a fluorescence in situ hybridization assay for the detection of dysplasia and adenocarcinoma in Barrett's esophagus

被引:44
作者
Brankley, Shannon M.
Wang, Kenneth K.
Harwood, Aaron R.
Miller, Dylan V.
Legator, Mona S.
Lutzke, Lori S.
Kipp, Benjamin R.
Morrison, Larry E.
Halling, Kevin C.
机构
[1] Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Rochester, MN 55902 USA
[2] Mayo Clin & Mayo Fdn, Dept Gastroenterol, Rochester, MN 55902 USA
[3] Vysis Abbott Molecular, Des Plaines, IL USA
关键词
D O I
10.2353/jmoldx.2006.050118
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The goal of this study was to identify a set of fluorescence in situ hybridization probes for the detection of dysplasia and adenocarcinoma in patients with Barrett's esophagus. We examined 170 brushing specimens from 138 patients with Barrett's esophagus or a history of Barrett's esophagus using fluorescence in situ hybridization with probes to 5P15, 5q21-22, centromere 7, 7p12, 8q24.12-13, centromere 9, 9p21, centromere 17, 17p13.1, 17q11.2-12, 20q13.2, and centromere Y. Receiver-operator curves were used to determine the sensitivity and specificity of various four-probe combinations for detecting low-grade dysplasia, high-grade dysplasia, and esophageal adenocarcinoma. Endoscopic biopsy results were used as the gold standard. Numerous four-probe combinations provided a similarly high sensitivity and specificity. Of these, a set consisting of probes to 8q24, 9p21, 17q11.2, and 20q13.2 was found to have a sensitivity and specificity, respectively, of 70% and 89% for low-grade dysplasia, 84% and 93% for high-grade dysplasia, and 94% and 93% for esophageal adenocarcinoma. This probe set was chosen for future prospective clinical evaluations based on its high sensitivity and specificity, its ability to distinguish adenocarcinoma and high-grade or low-grade dysplasia from lesser diagnostic categories, and the favorable signal quality for each of the probes.
引用
收藏
页码:260 / 267
页数:8
相关论文
共 38 条
  • [1] Barrett MT, 1996, ONCOGENE, V13, P1867
  • [2] p16 inactivation by methylation of the CDKN2A promoter occurs early during neoplastic progression in Barrett's esophagus
    Bian, YS
    Osterheld, MC
    Fontolliet, C
    Bosman, FT
    Benhattar, J
    [J]. GASTROENTEROLOGY, 2002, 122 (04) : 1113 - 1121
  • [3] BLOUNT PL, 1991, CANCER RES, V51, P5482
  • [4] Bubendorf L, 2001, AM J CLIN PATHOL, V116, P79
  • [5] THE INCIDENCE OF ADENOCARCINOMA IN COLUMNAR-LINED (BARRETTS) ESOPHAGUS
    CAMERON, AJ
    OTT, BJ
    PAYNE, WS
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1985, 313 (14) : 857 - 859
  • [6] Analysis of the premalignant stages of Barrett's oesophagus through to adenocarcinoma by comparative genomic hybridization
    Croft, J
    Parry, EM
    Jenkins, GJS
    Doak, SH
    Baxter, JN
    Griffiths, AP
    Brown, TH
    Parry, JM
    [J]. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2002, 14 (11) : 1179 - 1186
  • [7] Chromosome 4 hyperploidy represents an early genetic aberration in premalignant Barrett's oesophagus
    Doak, SH
    Jenkins, GJS
    Parry, EM
    D'Souza, FR
    Griffiths, AP
    Toffazal, N
    Shah, V
    Baxter, JN
    Parry, JM
    [J]. GUT, 2003, 52 (05) : 623 - 628
  • [8] Drewitz DJ, 1997, AM J GASTROENTEROL, V92, P212
  • [9] Chromosomal gains and genomic loss of p53 and p16 genes in Barrett's esophagus detected by fluorescence in situ hybridization of cytology specimens
    Fahmy, M
    Skacel, M
    Gramlich, TL
    Brainard, JA
    Rice, TW
    Goldblum, JR
    Connor, JT
    Casey, G
    Legator, MS
    Tubbs, RR
    Falk, GW
    [J]. MODERN PATHOLOGY, 2004, 17 (05) : 588 - 596
  • [10] Surveillance of patients with Barrett's esophagus for dysplasia and cancer with balloon cytology
    Falk, GW
    Chittajallu, R
    Goldblum, JR
    Biscotti, CV
    Geisinger, KR
    Petras, RE
    Birgisson, S
    Rice, TW
    Richter, JE
    [J]. GASTROENTEROLOGY, 1997, 112 (06) : 1787 - 1797